Pfizer Licenses the IDBS BioBook™
News Apr 12, 2006
IDBS has announced that Pfizer Global R&D has licensed the IDBS BioBook™ global electronic experiment and study management software.
BioBook is being deployed across the full spectrum of research biology; including discovery biology, worldwide safety sciences, pharmacokinetics dynamics and metabolism, and secondary and safety pharmacology.
IDBS claims that, users of BioBook can manage every aspect of their complex late stage research. As part of the global contract, BioBook will be used across all of Pfizer’s research sites worldwide, with IDBS delivering implementation and support services.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.